Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being -
SDG 7 Affordable and Clean Energy -
SDG 11 Sustainable Cities and Communities
Fingerprint
The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)
Kim, H. J. (PI)
BOEHRINGER-INGELHEIM PHARMACEUTICALS
6/1/26 → 5/31/36
Project: Research project
-
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis
Kim, H. J. (PI)
BOEHRINGER-INGELHEIM PHARMACEUTICALS
11/1/25 → 11/30/35
Project: Research project
-
A double-blind, randomized, placebo-controlled, parallel group, Phase IIa trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics and efficacy of BI 765423 administered intravenously on top of standard of care in patients with IPF
Kim, H. J. (PI)
BOEHRINGER-INGELHEIM PHARMACEUTICALS
9/1/25 → 12/31/27
Project: Research project
-
A Phase 2, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosi
Kim, H. J. (PI)
NOVARTIS PHARMACEUTICALS CORPORATION
4/1/25 → 12/31/32
Project: Research project
-
Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry
Nick, P., Studnicka, M., Gregor, J., Ovesná, P., Vašáková, M. K., Simmons, W., Li, Y., Strek, M. E., Li, P., Snyder, L. D., Olson, A. L., Kim, H. J. & Kaner, R. J., Jan 2026, In: ERJ Open Research. 12, 1, 00402-2025.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry
the ILD-PRO Registry investigators, Dec 2026, In: Lung. 204, 1, 32.Research output: Contribution to journal › Article › peer-review
Open Access -
Caring for Rural Patients With Interstitial Lung Disease: Perspectives of Pulmonary Fibrosis Foundation Care Center Network Nurses and Providers
Pulmonary Fibrosis Foundation Rural Health Outreach Committee, Sep 2025, In: CHEST Pulmonary. 3, 3, 100136.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Comparison of interstitial lung disease diagnoses in urban and rural areas among participants in the pulmonary fibrosis foundation patient registry
Dimmock, A. E. F., Furuya, Y., White, E., Freiheit, E., Bascom, R. & Kim, H. J., Feb 28 2025, In: Heliyon. 11, 4, e42667.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
Incidental radiologic evidence of interstitial lung disease and time to pulmonary evaluation
Kummer, R., Kubbara, A., Tessier, K. M., Meehan, T., Tholkes, A., Janssen, K. & Kim, H., Dec 2025, In: Respiratory research. 26, 1, 309.Research output: Contribution to journal › Article › peer-review
Open Access